



PROJECT DOCUMENT
Turkmenistan

Project Title: Ensuring universal access to high-quality diagnosis and treatment of drug resistant tuberculosis (DR-TB) in Turkmenistan

Project Number: 00100807

Implementing Partner: Ministry of Health and Medical Industry of Turkmenistan, Ministry of Internal Affairs of Turkmenistan, National Red Crescent Society of Turkmenistan and World Health Organization

Start Date: 01 July 2016

End Date: 30 June 2018

CCM Meeting date: 27 June 2016

Brief Description

Turkmenistan is one of 18 high priority countries of the WHO European Region's Plan to Stop TB, 2007–2015. Multi-drug resistant TB (MDR-TB) burden remains a key challenge. The first drug resistance survey conducted in 2013 detected 13.9% MDR prevalence among new and 37.6% prevalence among retreatment cases. Treatment of MDR-TB patients started in the country in 2013, and as of end 2015 the number of MDR-TB patients enrolled on treatment was 614. With the support of WHO, the country has developed the National Strategic Plan (NSP) for 2016-2020. The current project financed by the Global Fund to fight AIDS, TB and malaria is a key means for assisting country in its efforts to controlling drug-resistant tuberculosis. The goal of the project is to decrease the burden of tuberculosis in Turkmenistan by ensuring universal access to timely and quality diagnosis and treatment of drug-resistant forms of tuberculosis. This grant covers interventions in both civilian and penitentiary sectors. The project is aligned with the new National Tuberculosis Control Program in Turkmenistan 2016-2020 and is organized around three main Objectives:




- To ensure universal access to early and quality diagnosis of all forms of TB;
- To ensure universal access to quality patient-centered treatment of all forms of TB;
- To strengthen the program management, M&E and improve the health system's performance for effective TB control.

The project will contribute to achievement of the NSP targets: (i) decreasing the targets for TB mortality and incidence rates to 2.4 and 56 per 100,000 respectively, by 2020; and (ii) achieving 90% case detection and 75% treatment success rate for MDR-TB by 2020. These targets will be attained by ensuring universal access to high quality TB care for all TB patients, with emphasis on quality patient-oriented treatment.

Contributing Outcome (UNDAF/CPD, RPD or GPD):
CPAP Outcome #3 (UNPFD/CPD outcome #8): State institutions implement and monitor laws, national programmes, and strategies, in a participatory manner in line with the country's human rights commitments.
Indicative Output(s): 4.7 TB and MDR-TB incidence rate disaggregated by sex, education, age and urban/rural groups: Baseline: 42.6/100.000 (2014), Target: 20% reduction of 2014 baseline by 2020; 3.3.1: Number of MDR-TB patients enrolled in treatment (CPD 8.3.1): Baseline 210, target 848.

Total resources required:		USD 5,283,989
Total resources allocated:	UNDP TRAC:	0
	GFATM	USD
	Incremental funding:	4,089,307
	Phase II savings:	1,194,682
	Government:	0
	In-Kind:	0
	Other	0
Unfunded:		

Agreed by (signatures)¹:

Government	UNDP
Mr. Nurmuhammet Amanjpesov, Minister of Health and Medical Industry of Turkmenistan 	Ms. Jacinta Barrins, UNDP Resident Representative 
Date:	 10/2016

¹ Note: Adjust signatures as needed

Annual Work Plan for the UNDP TB Project financed by the Global Fund for 01.07.2016 - 30.06.2018

Activity Nr	Activity	Implementer	2016			2017				2018			Total for grant	
			Q1	Q2	2016	Q3	Q4	Q5	Q6	2017	Q7	Q8		2018
			01/06/16-30/09/16	01/10/16-31/12/16		01/01/17-31/03/17	01/04/17-30/06/17	01/07/17-30/09/17	01/10/17-31/12/17	01/01/18-31/03/18	01/04/18-30/06/18	2018		
ACTIVITY4	Procurement of drugs for treatment of MDR-TB, pre-XDR-TB and XDR-TB.	UNDP		696,607	696,607				661,802					1,358,409
ACTIVITY4	Procurement of water for injections and disposable syringes for M/XDR-TB treatment	UNDP				9,839			3,363					17,020
ACTIVITY4	Procurement of disposable face masks for M/XDR-TB patients to ensure infection control at TB hospitals.	UNDP	4,910		4,910									4,910
ACTIVITY4	Laboratory reagents: procurement of reagents for automated culture investigations and drug resistance testing: MGIT technique (Bactec-960), PCR (Hain) and Xpert, at the NRL and regional TB laboratories.	UNDP				165,945			164,969				249,808	580,721
ACTIVITY4	Consumables and N95/FFP2 respirators for NRL and regional TB laboratories.	UNDP		5,148	5,148	5,501			5,338				7,587	23,573
ACTIVITY4	Maintenance and service costs for health equipment	UNDP	46,000		46,000				24,000					70,000
ACTIVITY4	PSM for health products	UNDP	12,417	96,179	108,595	43,254			33,278				44,804	319,172
ACTIVITY4	SLD PO carryover to NFM	UNDP	798,119		798,119									798,119
ACTIVITY4	Reagents PO carryover to NFM	UNDP	126,980		126,980									126,980
ACTIVITY1	External technical assistance from the SRL Gauting to improve performance of the country's TB laboratory network	WHO					8,788						8,900	17,688
ACTIVITY2	Updating of national TB laboratory guidelines	UNDP		1,500	1,500									1,500
ACTIVITY1	External Quality Control of second line TB drugs procured with the grant support	UNDP				2,556							2,556	5,112
ACTIVITY1	Annual Green Light Committee operations fee	UNDP	25,000	25,000	50,000								25,000	75,000
ACTIVITY1	Incentives to M/XDR-TB patients	NRCS	21,396	21,396	42,792	35,291	35,291	35,291	35,291	35,291	35,291	34,430	68,861	252,818
ACTIVITY1	Conduct MDR-TB patients education and counselling sessions by adherence counsellors-stationary	NRCS	3,491	3,491	6,981	3,491	3,491	3,491	3,491	3,491	3,491	3,491	3,491	27,924
ACTIVITY1	Travel costs for home visits to M/XDR-TB patients on ambulatory treatment by adherence counsellors	NRCS	16,405	16,405	32,811	17,171	17,171	17,171	17,171	17,171	17,171	17,978	17,978	137,450
ACTIVITY1	Operational expenses of the SR NRCS	NRCS	25,814	25,814	51,628	28,083	28,083	28,083	28,083	28,083	28,083	30,587	61,173	225,133
ACTIVITY1	Capacity building of PHC staff: local training	WHO		7,041	7,041		3,520		7,041			3,520		21,122
ACTIVITY2	Support to the development of the national plan for sustainability of TB control programme	UNDP		10,250	10,250									10,250
ACTIVITY2	Revision / update of regulatory documents, health system's functions and TB control	WHO	5,350	4,750	10,100									10,100
ACTIVITY4	Local consultant to facilitate implementation of M/XDR-TB programmatic management	UNDP	600	900	1,500	900	900	900	900	900	900	900	600	6,600